The State of Translational Research


report imageThe blog post title above is also the title of a report by Sigma-Aldrich (published with partners AAAS and Science). The report is based on 608 survey respondents, 45% of which were in the US; 23% of respondents were graduate students. It’s not so long, as reports go, and you might easily read it on the bus or while eating lunch. I’ll give you a few nuggets from the report here to whet your appetite.

When asked about their barriers to progressing their research, 62% of respondents named insufficient funding, with inappropriate duration of grants and insufficient scope of grants coming next, both with 18%. Twenty-two percent of responders said their funding for translational research decreased over the past 12 months (17% said it increased). Also, the majority of respondents (62%) said that collaboration with their business school would benefit their research groups, but only 13% are actually collaborating.

That last bit of information Pat Sullivan found shocking. He’s the former liaison for academic partnerships at Pfizer and now works for Sigma-Aldrich. He thinks there is an opportunity for pharma to help educate universities on how to best fill the voids in research left by pharma cutbacks.

I asked him for further thoughts on the report, and he supplied this:

Through aggressive downsizing, Pharma has reduced its capacity to identify new commercially viable therapeutic disease targets and new drug candidates. These reduced capabilities have driven Large Pharma to seek out new partnerships with academic researchers working in the translational research fields. However, in order to take full advantage of this new opportunity, academic researchers and institutions will need to conduct their research programs in a new way. In fact, they will have to model and conduct their translational research programs after the processes and workflows currently being used in Large Pharma. This will require the translational researcher to work on interdisciplinary scientific teams and with non-scientific departments like their Business and Law schools. Institutions that set up their programs to promote collaborations across departments will learn how to leverage their scientific discoveries into commercial opportunities. They will also learn how to choose external partners to help them to generate quality data and obtain key reagents needed to attract Pharma collaborations and funding. Institutions and Funding agencies will also have to support Principal Investigators seeking to work in the translational research field by recognizing contributions beyond just publishing.  

Eventually, institutions that conduct translational research will learn to focus their programs on the drug development process that will be the most efficient for them to execute and add the most value to Large Pharma. In most cases, they will focus their programs on the early drug development phases involving new disease target validation and lead chemistry discovery. If the translational research program focuses on an orphan disease, it will be required to work with several external partners to conduct preclinical and clinical activities and obtain manufacturing capabilities.  

Thoughts? You can access the report at the link below.

Enjoy your lunch,

Brady Huggett

Translational Research report

Please sign in or register for FREE

If you are a registered user on Nature Portfolio Bioengineering Community, please sign in